| |
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio庐 (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF庐 (trifarotene)1-8
Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil庐 in different skin types9
Data from Galderma |
| |
| |
| |
| 上一篇：Venture Global与Vitol宣布达成新液化天然气采购协议 |
| 下一篇：Galderma Receives U.S. FDA Approval for Restylane Contour for the Correction of Temple Hollowing |
| |
| |
| |
